Human Genome Epidemiology Literature Finder
Records 1 - 30 (of 81 Records) |
Query Trace: Disease Progression and PIK3CA[original query] |
---|
PIK3CA mutations in plasma circulating tumor DNA predict survival and treatment outcomes in patients with advanced cancers. ESMO open 2021 9 6 (5): 100230. Dumbrava E E, Call S G, Huang H J, Stuckett A L, Madwani K, Adat A, Hong D S, Piha-Paul S A, Subbiah V, Karp D D, Fu S, Naing A, Tsimberidou A M, Moulder S L, Koenig K H, Barcenas C H, Kee B K, Fogelman D R, Kopetz E S, Meric-Bernstam F, Janku |
PIK3CA mutation in non-metastatic triple-negative breast cancer as a potential biomarker of early relapse: A case report. World journal of clinical oncology 2021 Aug 12 (8): 702-711. Valencia Guillermo Arturo, Rioja Patricia, Morante Zaida, Araujo Jhajaira M, Vallejos Heberth Daniel, Guerra Henry, Gomez Henry |
Genetic characteristics and response to systemic therapies of acral lentiginous melanoma at a tertiary care center-a retrospective review. Journal of the National Medical Association 2021 Sep . Jamerson Taylor, Rebecca Vito W, Aguh Cryst |
Cross-platform comparison of next-generation sequencing and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry for detecting KRAS/NRAS/BRAF/PIK3CA mutations in cfDNA from metastatic colorectal cancer patients. Journal of clinical laboratory analysis 2021 Aug e23818. Xu Xiaojing, Huang Fei, Cao Minlu, Chen Xinning, Wang Hao, Jiang Huiqin, Yu Yiyi, Shen Minna, Yang Yihui, Wang Beili, Liu Tianshu, Guo W |
Mutations of METTL3 predict response to neoadjuvant chemotherapy in muscle-invasive bladder cancer. Journal of clinical and translational research 2021 7 7 (3): 386-413. Yang Zhao, Shen Zongyi, Jin Di, Zhang Nan, Wang Yue, Lei Wanjun, Zhang Zhiming, Chen Haige, Naz Faiza, Xu Lida, Wang Lei, Wang Shihui, Su Xin, Yu Changyuan, Li Cho |
Prognosis and Concurrent Genomic Alterations in Patients With Advanced NSCLC Harboring MET Amplification or MET Exon 14 Skipping Mutation Treated With MET Inhibitor: A Retrospective Study. Frontiers in oncology 2021 7 11 649766. Liu Li, Kalyani Farhin Shaheed, Yang Haiyan, Zhou Chunhua, Xiong Yi, Zhu Songlin, Yang Nong, Qu Jingji |
NGS-based liquid biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step toward personalized NSCLC treatment. Molecular oncology 2021 May . Sánchez-Herrero Estela, Serna-Blasco Roberto, Ivanchuk Vadym, García-Campelo Rosario, Dómine Gómez Manuel, Sánchez José M, Massutí Bartomeu, Reguart Noemi, Camps Carlos, Sanz-Moreno Sandra, Calabuig-Fariñas Silvia, Jantus-Lewintre Eloísa, Arnal Magdalena, Fernández-Orth Dietmar, Calvo Virginia, González-Rumayor Víctor, Provencio Mariano, Romero Atoc |
Shallow WGS of individual CTCs identifies actionable targets for informing treatment decisions in metastatic breast cancer. British journal of cancer 2022 Sep . Fernandez-Garcia Daniel, Nteliopoulos Georgios, Hastings Robert K, Rushton Amelia, Page Karen, Allsopp Rebecca C, Ambasager Bana, Gleason Kelly, Guttery David S, Ali Simak, Charles Coombes R, Shaw Jacqueline |
Elevated serum CEA is associated with liver metastasis and distinctive circulating tumor DNA alterations in patients with castration-resistant prostate cancer. The Prostate 2022 6 82 (13): 1264-1272. Bray Alexander W, Duan Rong, Malalur Pannaga, Drusbosky Leylah M, Gourdin Theodore S, Hill Elizabeth G, Lilly Michael |
Genomic Alteration Spectrum of Non-Small Cell Lung Cancer Patients in East-China Characterized by Tumor Tissue DNA and Cell-Free DNA. OncoTargets and therapy 2022 5 15 571-584. Li Jie, Chen Siwen, Xue Hui, Wang Haoyi, Huang Tianwei, Xie Hongya, He Jiang, Ke Cai, Yu Zhaonan, Ni B |
Identification of mutation patterns and circulating tumour DNA-derived prognostic markers in advanced breast cancer patients. Journal of translational medicine 2022 05 20 (1): 211. Liao Hao, Zhang Jiayang, Zheng Tiantian, Liu Xiaoran, Zhong Jianxin, Shao Bin, Dong Xiaoxi, Wang Xiaohong, Du Pan, King Bonnie L, Jia Shidong, Yu Jianjun, Li Huipi |
Clinical Utility of Genomic Profiling Tests in Patients with Advanced Gastrointestinal Cancers. Targeted oncology 2022 4 17 (2): 177-185. Takeda Hiroyuki, Imoto Kiyomi, Umemoto Kumiko, Doi Ayako, Arai Hiroyuki, Horie Yoshiki, Mizukami Takuro, Oguri Tomoyo, Ogura Takashi, Izawa Naoki, Yamamoto Hiroyuki, Yamano Yoshihisa, Sunakawa |
Phase II Study of Taselisib in PIK3CA-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I. JCO precision oncology 2022 2 6 e2100424. Krop Ian E, Jegede Opeyemi A, Grilley-Olson Juneko E, Lauring Josh D, Mitchell Edith P, Zwiebel James A, Gray Robert J, Wang Victoria, McShane Lisa M, Rubinstein Larry V, Patton David, Williams P Mickey, Hamilton Stanley R, Kono Scott A, Ford James M, Garcia Agustin A, Sui Xingwei D, Siegel Robert D, Slomovitz Brian M, Conley Barbara A, Arteaga Carlos L, Harris Lyndsay N, O'Dwyer Peter J, Chen Alice P, Flaherty Keith |
Antitumor activity and safety of sirolimus for solid tumors with PIK3CA mutations: A multicenter, open-label, prospective single-arm study (KM 02-01, KCSG UN17-16). Translational cancer research 2022 2 9 (5): 3222-3230. Byeon Seonggyu, Kang Myoung Joo, Choi Yoon Ji, Kim Yu Jung, Kim Miso, Yun Jina, Yi Seong Yoon, Kim Jin Young, Kim Seung Tae, Lee Jeey |
Using Tumor-Informed Circulating Tumor DNA (ctDNA)-Based Testing for Patients with Anal Squamous Cell Carcinoma. The oncologist 2022 12 . Azzi Georges, Tavallai Mehrad, Aushev Vasily N, Koyen Malashevich Allyson, Botta Gregory P, Tejani Mohamedtaki A, Hanna Diana, Krinshpun Shifra, Malhotra Meenakshi, Jurdi Adham, Aleshin Alexey, Kasi Pashtoon |
Evaluation of alpelisib-induced hyperglycemia prophylaxis and associated risk factors in PIK3CA-mutated hormone-receptor positive, human epidermal growth factor-2 negative advanced breast cancer. Breast cancer research and treatment 2022 11 197 (2): 369-376. Burnette Sarah E, Poehlein Emily, Lee Hui-Jie, Force Jeremy, Westbrook Kelly, Moore Heather |
Dynamic Monitoring of Circulating Tumor DNA in Patients With Metastatic Colorectal Cancer. JCO precision oncology 2023 9 7 e2200694. Milena Urbini, Giorgia Marisi, Irene Azzali, Giulia Bartolini, Elisa Chiadini, Laura Capelli, Gianluca Tedaldi, Davide Angeli, Matteo Canale, Chiara Molinari, Francesca Rebuzzi, Alessandra Virga, Andrea Prochowski Iamurri, Laura Matteucci, Francesco Giulio Sullo, Silvia Angela Debonis, Chiara Gallio, Giovanni Luca Frassineti, Giovanni Martinelli, Paola Ulivi, Alessandro Passar |
Monitoring the Outcomes of Systemic Chemotherapy Including Immune Checkpoint Inhibitor for HER2-Positive Metastatic Gastric Cancer by Liquid Biopsy. Yonsei medical journal 2023 8 64 (9): 531-540. Seung-Hyun Jung, Choong-Kun Lee, Woo Sun Kwon, Sujin Yun, Minkyu Jung, Hyo Song Kim, Hyun Cheol Chung, Yeun-Jun Chung, Sun Young R |
Prognostic impact of molecular profiles and molecular signatures in clear cell ovarian cancer. Cancer genetics 2023 8 278-279 9-16. Tine Henrichsen Schnack, Douglas-V N P Oliveira, Anne Pernille Christiansen, Claus Høgdall, Estrid Høgda |
Plasma cell-free tumor DNA, PIK3CA and TP53 mutations predicted inferior endocrine-based treatment outcome in endocrine receptor-positive metastatic breast cancer. Breast cancer research and treatment 2023 6 . Tom Wei-Wu Chen, Wen Hsiao, Ming-Shen Dai, Ching-Hung Lin, Dwan-Ying Chang, I-Chun Chen, Ming-Yang Wang, Shu-Han Chang, Shu-Min Huang, Ann-Lii Cheng, Ko-Wen Wu, Kien Thiam Tan, Yen-Shen |
Genomic analysis of plasma circulating tumor DNA in patients with heavily pretreated HER2?+?metastatic breast cancer. Scientific reports 2023 6 13 (1): 9928. Kyoungmin Lee, Jongwon Lee, Jungmin Choi, Sung Hoon Sim, Jeong Eun Kim, Min Hwan Kim, Yeon Hee Park, Jee Hyun Kim, Su-Jin Koh, Kyong Hwa Park, Myoung Joo Kang, Mi Sun Ahn, Kyoung Eun Lee, Hee-Jun Kim, Hee Kyung Ahn, Han Jo Kim, Keon Uk Park, In Hae Pa |
Panitumumab Plus Trifluridine-Tipiracil as Anti-Epidermal Growth Factor Receptor Rechallenge Therapy for Refractory RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial. JAMA oncology 2023 5 . Stefania Napolitano, Vincenzo De Falco, Giulia Martini, Davide Ciardiello, Erika Martinelli, Carminia Maria Della Corte, Lucia Esposito, Vincenzo Famiglietti, Alessandra Di Liello, Antonio Avallone, Claudia Cardone, Alfonso De Stefano, Vincenzo Montesarchio, Maria Giulia Zampino, Roberto Bordonaro, Mario Scartozzi, Daniele Santini, Massimo Di Maio, Ferdinando De Vita, Lucia Altucci, Francesca Marrone, Fortunato Ciardiello, Teresa Troia |
Genomic landscape and survival analysis of ctDNA "neo-RAS wild-type" patients with originally RAS mutant metastatic colorectal cancer. Frontiers in oncology 2023 4 13 1160673. Nicolazzo Chiara, Magri Valentina, Marino Luca, Belardinilli Francesca, Di Nicolantonio Federica, De Renzi Gianluigi, Caponnetto Salvatore, De Meo Michela, Giannini Giuseppe, Santini Daniele, Cortesi Enrico, Gazzaniga Pao |
Trametinib in Patients With NF1-, GNAQ-, or GNA11-Mutant Tumors: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols S1 and S2. JCO precision oncology 2023 4 7 e2200421. Wisinski Kari B, Flamand Yael, Wilson Melissa A, Luke Jason J, Tawbi Hussein A, Hong Fangxin, Mitchell Edith P, Zwiebel James A, Chen Helen, Gray Robert J, Li Shuli, McShane Lisa M, Rubinstein Lawrence V, Patton David, Williams P Mickey, Hamilton Stanley R, Behrens Robert J, Pennington Kathryn P, Conley Barbara A, Arteaga Carlos L, Harris Lyndsay N, O'Dwyer Peter J, Chen Alice P, Flaherty Keith |
Serial circulating-tumor DNA analysis with a tumor naïve next-generation sequencing panel detects minimal residual disease and predicts outcome in ovarian cancer. Cancer research 2023 12 . Jinho Heo, Yoo-Na Kim, Saeam Shin, Kyunglim Lee, Ji-Hyun Lee, Yong Jae Lee, Zisun Choi, Jihyang Park, Seungki Min, Sang Wun Kim, Jong Rak Choi, Sunghoon Kim, Seung-Tae Lee, Jung-Yun L |
Predictive biomarkers of response and survival following immunotherapy with a PD-L1 inhibitor benmelstobart (TQB2450) and antiangiogenic therapy with a VEGFR inhibitor anlotinib for pretreated advanced triple negative breast cancer. Signal transduction and targeted therapy 2023 11 8 (1): 429. Yiqun Han, Jiayu Wang, Tao Sun, Quchang Ouyang, Jianwen Li, Jie Yuan, Binghe |
Changes in cell-free DNA after short-term palbociclib and fulvestrant treatment for advanced or metastatic hormone receptor-positive and human epidermal growth factor 2-negative breast cancer. Breast cancer research and treatment 2023 10 . Takayuki Iwamoto, Naoki Niikura, Kenichi Watanabe, Takashi Takeshita, Yuichiro Kikawa, Kokoro Kobayashi, Nobutaka Iwakuma, Takuho Okamura, Hiroshi Tada, Shinji Ozaki, Toshitaka Okuno, Uhi Toh, Yutaka Yamamoto, Michiko Tsuneizumi, Hiroshi Ishiguro, Norikazu Masuda, Shigehira Sa |
Cerebrospinal fluid-derived circulating tumor DNA is more comprehensive than plasma in NSCLC patients with leptomeningeal metastases regardless of extracranial evolution. Heliyon 2023 1 8 (12): e12374. Yang Hainan, Wen Lei, Zhao Chao, Chen Jianing, Zhou Zhaoming, Zhou Cheng, Cai Linbo, Zhou Caic |
Monitoring ctDNA RAS Mutational Status in Metastatic Colorectal Cancer: A Trial Protocol of RAS-trace and RAS-trace-2 Studies. Journal of the anus, rectum and colon 2024 5 8 (2): 132-136. Kozo Kataoka, Takeshi Yamada, Manabu Shiozawa, Naoto Takase, Kazuma Ito, Kentaro Yamazaki, Jun Watanabe, Toshihiro Kudo, Takeshi Suto, Toshihiko Matsumoto, Kohei Murata, Yusuke Suwa, Shogen Boku, Hisateru Yasui, Nobuhisa Matsuhashi, Atsuyuki Maeda, Kiichi Sugimoto, Yusuke Matsumoto, Mitsuru Yokota, Johannes Fredebohm, Keita Mori, Masataka Ike |
Genomic Landscape of Circulating Tumor DNA in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-2-Negative Metastatic Breast Cancer Treated With Abemaciclib: Data From the SCRUM-Japan Cancer Genome Screening Project. JCO precision oncology 2024 4 8 e2300647. Masaya Hattori, Victoria Serelli-Lee, Yoichi Naito, Takashi Yamanaka, Hiroyuki Yasojima, Rikiya Nakamura, Takao Fujisawa, Mitsuho Imai, Yoshiaki Nakamura, Hideaki Bando, Tsutomu Kawaguchi, Takayuki Yoshino, Hiroji Iwa |
- Page last reviewed:Feb 1, 2024
- Page last updated:May 06, 2024
- Content source: